title: Discovery of indeno[1, 2 - c] quinoline derivatives as dual topoisomerases I/II inhibitors: part 3.
abstract: (E) -6-Hydroxy-9-methoxy-6-(piperazin-1-yl)-11H -indeno[1,2-c ]quinolin-11-one O-2-(pyrrolidin-1-yl)ethyl oxime (2c) was identified as a potential dual topo I/II inhibitor in our previous paper. In continuation for the search of more potent compounds, we describe herein the preparation of certain indeno[1,2-c ]quinoline derivatives and evaluation of their antiproliferation, DNA binding affinity, and topoisomerases (topo I and topo II) inhibitory activities. Among them, (E) -9-[3-(dimethylamino)propoxy]-11H -indeno[1,2-c ]quinolin-11-one O-3-(dimethylamino)propyl oxime (11b) and its analog 11c exhibited approximately equal activity to the lead compound 2c against the growth of HeLa and A549 cancer cells. Both compounds 11b and 11c were more active than 2c in the inhibition of topo I and topo II. However, none of them exhibited significant DNA binding affinity while 2c was a very strong DNA binding agent. Compound 11b exhibited a high oral bioavailability of 39.8 % while the oral bioavailability of 2c and 11c was only 10.9 and 8.6 %, respectively. The in vivo anti-tumor evaluation of 11b in nude mice bearing subcutaneous breast cancer tumors revealed that treatment with low (10 mg/kg) or high (30 mg/kg) doses of 11b dramatically diminished tumor growth. Therefore, compound 11b is identified as a potential non-DNA intercalating dual topo I/II inhibitor.
authors.forename: Chih-Hua
authors.initials: CH
authors.lastname: Tseng
authors.forename: Cherng-Chyi
authors.initials: CC
authors.lastname: Tzeng
authors.forename: Chiao-Li
authors.initials: CL
authors.lastname: Yang
authors.forename: Pei-Jung
authors.initials: PJ
authors.lastname: Lu
authors.forename: Yu-Peng
authors.initials: YP
authors.lastname: Liu
authors.forename: Hui-Ling
authors.initials: HL
authors.lastname: Chen
authors.forename: Chien-Yu
authors.initials: CY
authors.lastname: Chen
authors.forename: Chia-Ning
authors.initials: CN
authors.lastname: Yang
authors.forename: Yeh-Long
authors.initials: YL
authors.lastname: Chen
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology; D045744:Cell Line, Tumor; D006801:Humans; D008297:Male; D051379:Mice; D008958:Models, Molecular; D008968:Molecular Conformation; D015394:Molecular Structure; D011804:Quinolines / Q000737:chemistry* / Q000494:pharmacology; D059004:Topoisomerase I Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D059005:Topoisomerase II Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D011804:Quinolines; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors
references.citation: Biochem J. 2002 Sep 1;366(Pt 2):653-61
references.pmid: 12027807
references.citation: J Biol Chem. 2002 Jan 25;277(4):2381-4
references.pmid: 11723108
references.citation: Biochim Biophys Acta. 2002 Jul 18;1587(2-3):155-63
references.pmid: 12084457
references.citation: Bioorg Med Chem. 2009 Oct 15;17(20):7145-55
references.pmid: 19783447
references.citation: Bioorg Med Chem. 2009 Apr 1;17(7):2877-85
references.pmid: 19303306
references.citation: Biochemistry. 1999 Nov 23;38(47):15573-9
references.pmid: 10569941
references.citation: Eur J Med Chem. 2009 May;44(5):2280-5
references.pmid: 18692939
references.citation: J Med Chem. 2008 Jun 26;51(12):3617-29
references.pmid: 18507368
references.citation: J Med Chem. 2011 Apr 28;54(8):3103-7
references.pmid: 21456521
references.citation: J Biol Chem. 2005 Jan 14;280(2):1179-85
references.pmid: 15533934
references.citation: J Med Chem. 2010 Apr 22;53(8):3048-64
references.pmid: 20353152
references.citation: Eur J Med Chem. 2010 Jun;45(6):2223-8
references.pmid: 20202723
references.citation: Mol Pharmacol. 2008 Mar;73(3):987-94
references.pmid: 18089836
references.citation: Bioorg Med Chem Lett. 2002 Feb 11;12(3):415-8
references.pmid: 11814810
references.citation: Pharmacol Ther. 1987;32(2):89-106
references.pmid: 3037573
references.citation: Cancer Res. 2007 Oct 15;67(20):9971-9
references.pmid: 17942930
references.citation: Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1470-4
references.pmid: 8108433
references.citation: J Med Chem. 2002 Jan 31;45(3):721-39
references.pmid: 11806724
references.citation: J Am Chem Soc. 1988 Aug 1;110(18):5959-67
references.pmid: 22148765
references.citation: Jpn J Cancer Res. 1999 May;90(5):578-87
references.pmid: 10391099
references.citation: Jpn J Cancer Res. 1997 Oct;88(10):992-1002
references.pmid: 9414662
references.citation: J Med Chem. 2010 Mar 25;53(6):2589-600
references.pmid: 20170164
references.citation: J Med Chem. 2009 May 28;52(10):3225-37
references.pmid: 19397324
references.citation: Bioorg Med Chem. 2009 Oct 1;17(19):7052-5
references.pmid: 19736019
references.citation: Bioorg Med Chem. 2010 Mar 15;18(6):2245-2254
references.pmid: 20188578
references.citation: Bioorg Med Chem. 2009 Oct 15;17(20):7131-7
references.pmid: 19783445
references.citation: J Med Chem. 2010 Aug 26;53(16):6164-79
references.pmid: 20662543
references.citation: Eur J Med Chem. 2009 Sep;44(9):3433-8
references.pmid: 19299037
references.citation: Bioorg Med Chem. 2009 May 1;17(9):3266-77
references.pmid: 19364657
references.citation: Biochem Pharmacol. 2000 Apr 1;59(7):807-19
references.pmid: 10718339
references.citation: J Med Chem. 2009 Sep 24;52(18):5649-61
references.pmid: 19715319
references.citation: Bioorg Med Chem. 2010 May 1;18(9):3066-77
references.pmid: 20392646
references.citation: J Med Chem. 2010 May 13;53(9):3835-9
references.pmid: 20405921
references.citation: J Med Chem. 2010 Mar 11;53(5):1979-89
references.pmid: 20155916